• 1. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 2. An intermolecular C–H oxidizing strategy to access highly fused carbazole skeletons from simple naphthylamines?
  Christian K. Rank,Alexander W. Jones,Tatjana Wall,Patrick Di Martino-Fumo,Sarah Schr?ck,Markus Gerhards,Frederic W. Patureau Chem. Commun., 2019,55, 13749-13752
• 3. An aqueous ammonia sensor based on an inkjet-printed polyaniline nanoparticle-modified electrode
  Karl Crowley,Eimer O'Malley,Aoife Morrin,Malcolm R. Smyth,Anthony J. Killard Analyst, 2008,133, 391-399
• 4. Aggregation of biologically important peptides and proteins: inhibition or acceleration depending on protein and metal ion concentrations
  Benjamin Gabriel Poulson,Kacper Szczepski,Joanna Izabela Lachowicz,Lukasz Jaremko,Abdul-Hamid Emwas,Mariusz Jaremko RSC Adv., 2020,10, 215-227
• 5. An all-solid-state imprinted polymer-based potentiometric sensor for determination of bisphenol S?
  Rongning Liang,Tanji Yin,Ruiqing Yao,Wei Qin RSC Adv., 2016,6, 73308-73312

Introduction to 6-(pyridin-4-yl)-2-sulfanylidene-1,2,3,4-tetrahydropyrimidin-4-one (CAS No. 37039-71-7) and Its Emerging Applications in Chemical Biology

The compound 6-(pyridin-4-yl)-2-sulfanylidene-1,2,3,4-tetrahydropyrimidin-4-one, identified by its CAS number 37039-71-7, represents a fascinating molecule with significant potential in the realm of chemical biology and pharmaceutical research. This heterocyclic sulfonamide derivative combines the structural features of pyridine and tetrahydropyrimidine moieties, creating a versatile scaffold that has garnered attention for its biological activity and synthetic utility. The presence of a sulfanylidene group introduces unique reactivity, making this compound a promising candidate for further exploration in drug discovery and molecular medicine.

Recent advancements in medicinal chemistry have highlighted the importance of sulfonamide-containing compounds due to their broad spectrum of biological activities. The 6-(pyridin-4-yl)-2-sulfanylidene-1,2,3,4-tetrahydropyrimidin-4-one structure exemplifies how strategic modifications can enhance pharmacological properties. The pyridine ring not only contributes to solubility and metabolic stability but also serves as a hinge for binding to biological targets. This dual functionality has been exploited in the design of novel inhibitors targeting enzymes involved in cancer metabolism and inflammation.

In particular, the sulfanylidene moiety has been shown to exhibit strong interactions with metal ions and thiols, which are critical for numerous enzymatic processes. This characteristic makes 6-(pyridin-4-yl)-2-sulfanylidene-1,2,3,4-tetrahydropyrimidin-4-one a valuable scaffold for developing chelating agents or modulators of metal-dependent pathways. Current research is exploring its potential in combating metalloproteinase-mediated diseases, such as osteoarthritis and certain types of cancer. The tetrahydropyrimidine ring further enhances the compound's bioisosteric potential, allowing it to mimic natural substrates or transition states with high affinity.

One of the most compelling aspects of this compound is its role in addressing unmet medical needs through innovative chemical biology approaches. The CAS no 37039-71-7 identifier ensures precise identification and reproducibility in experimental settings. Researchers have leveraged this compound to develop novel prodrugs that release active species under physiological conditions, improving therapeutic efficacy while minimizing side effects. The pyridine-pyrimidine core has also been integrated into peptidomimetics designed to disrupt protein-protein interactions implicated in neurodegenerative disorders.

The synthetic pathways for 6-(pyridin-4-yl)-2-sulfanylidene-1,2,3,4-tetrahydropyrimidin-4-one have been refined to achieve high yields and purity, facilitating its use in both academic and industrial settings. Modern techniques such as transition-metal-catalyzed cross-coupling reactions have enabled the introduction of diverse substituents at the pyridine ring without compromising structural integrity. This modularity allows chemists to fine-tune physicochemical properties such as lipophilicity and polar surface area (PSA), optimizing drug-like characteristics for preclinical development.

Emerging data from preclinical studies suggest that derivatives of 6-(pyridin-4-yl)-2-sulfanylidene-1,2,3,4-tetrahydropyrimidin-4-one exhibit promising antitumor effects by inhibiting key metabolic enzymes overexpressed in cancer cells. The sulfonamide group acts as a pharmacophore for selective binding to target proteins while maintaining low toxicity profiles in healthy tissues. Computational modeling has further revealed that this scaffold can be engineered to enhance blood-brain barrier penetration, opening new avenues for treating central nervous system disorders.

The intersection of computational chemistry and experimental validation has accelerated the discovery pipeline for this class of compounds. High-throughput screening (HTS) combined with machine learning algorithms has identified lead candidates derived from CAS no 37039-71-7 that show exceptional binding affinity to disease-relevant targets. These computational strategies predict optimal analogs with minimal off-target effects, streamlining the iterative process of drug development.

Future directions in research may explore the use of 6-(pyridin-4-yl)-2-sulfanylidene-1,2,3,4-tetrahydropyrimidin-4-one as a building block for conjugated polymers or organic semiconductors with applications in bioimaging and photodynamic therapy. Its ability to form stable coordination complexes with transition metals could also be exploited in catalytic systems designed for sustainable chemical transformations. As synthetic methodologies continue to evolve, this compound will undoubtedly play a pivotal role in shaping next-generation therapeutics.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)